Companies › Imbioray (Hangzhou) Biomedicine
3 active drug programs in 3 registered trials: 2 Phase 1, 1 Phase 2; Oncology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| IBR854 Allogeneic anti-CD19 CAR-T cell therapy | – | Phase 2 | Renal Cell Carcinoma (RCC) | Dec 2026 |
| IBR733 Cell Injection Cell injection therapy | – | Phase 1 | Acute Myeloid Leukemia | Jul 2027 |
| IBR900 cell injection NK cell therapy | – | Phase 1 | Relapsed/Refractory B-cell Non-Hodgkin Lymphoma | Jul 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07087158 | IBR854 | Phase 2 | Renal Cell Carcinoma (RCC) | Oncology | Dec 2026 |
| NCT06234904 | IBR733 Cell Injection | Phase 1 | Acute Myeloid Leukemia | Oncology | Jul 2027 |
| NCT07073833 | IBR900 cell injection | Phase 1 | Relapsed/Refractory B-cell Non-Hodgkin Lymphoma | Oncology | Jul 2027 |
No annotated target.
–
Bio-Path Holdings Vividion Therapeutics GI Innovation Scancell Alpheus Medical
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.